Reviewing Lakefront Biotherapeutics American Depositary Shares (LKFT) and Its Competitors

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Lakefront Biotherapeutics American Depositary Shares to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Lakefront Biotherapeutics American Depositary Shares and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Lakefront Biotherapeutics American Depositary Shares Competitors	9874	15295	45659	1600	2.54

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $35.50, suggesting a potential upside of 4.47%. As a group, “Biotechnology” companies have a potential upside of 126.50%. Given Lakefront Biotherapeutics American Depositary Shares’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares has less favorable growth aspects than its rivals.

Risk & Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares’ rivals have a beta of -1.82, meaning that their average stock price is 282% less volatile than the S&P 500.

Institutional and Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	$363.05 million	-24.10
Lakefront Biotherapeutics American Depositary Shares Competitors	$702.34 million	$9.48 million	-18.76

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than its rivals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Lakefront Biotherapeutics American Depositary Shares Competitors	-12,323.33%	-195.91%	-30.60%

Summary

Lakefront Biotherapeutics American Depositary Shares rivals beat Lakefront Biotherapeutics American Depositary Shares on 7 of the 13 factors compared.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.